Insulet Corporation $PODD Shares Sold by Hsbc Holdings PLC

Hsbc Holdings PLC decreased its position in shares of Insulet Corporation (NASDAQ:PODD) by 32.3% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 124,514 shares of the medical instruments supplier’s stock after selling 59,379 shares during the period. Hsbc Holdings PLC’s holdings in Insulet were worth $35,424,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. Glenmede Investment Management LP boosted its stake in Insulet by 1.6% during the 3rd quarter. Glenmede Investment Management LP now owns 2,292 shares of the medical instruments supplier’s stock valued at $708,000 after purchasing an additional 35 shares in the last quarter. Curi Capital LLC raised its stake in shares of Insulet by 0.8% in the 2nd quarter. Curi Capital LLC now owns 4,346 shares of the medical instruments supplier’s stock worth $1,365,000 after buying an additional 36 shares in the last quarter. WINTON GROUP Ltd lifted its holdings in shares of Insulet by 0.9% in the third quarter. WINTON GROUP Ltd now owns 4,086 shares of the medical instruments supplier’s stock valued at $1,261,000 after buying an additional 37 shares during the period. Great Lakes Advisors LLC lifted its holdings in shares of Insulet by 1.5% in the fourth quarter. Great Lakes Advisors LLC now owns 2,784 shares of the medical instruments supplier’s stock valued at $791,000 after buying an additional 40 shares during the period. Finally, Camarda Financial Advisors LLC boosted its stake in Insulet by 0.5% during the second quarter. Camarda Financial Advisors LLC now owns 7,332 shares of the medical instruments supplier’s stock valued at $2,304,000 after buying an additional 40 shares in the last quarter.

Insulet Stock Down 2.9%

Shares of Insulet stock opened at $159.77 on Tuesday. Insulet Corporation has a 12-month low of $138.79 and a 12-month high of $354.88. The firm has a market capitalization of $11.07 billion, a PE ratio of 37.16, a price-to-earnings-growth ratio of 1.15 and a beta of 1.11. The company has a quick ratio of 1.81, a current ratio of 2.49 and a debt-to-equity ratio of 0.71. The stock’s fifty day moving average is $154.58 and its 200-day moving average is $214.47.

Insulet (NASDAQ:PODD) last released its quarterly earnings results on Wednesday, May 6th. The medical instruments supplier reported $1.42 earnings per share for the quarter, beating analysts’ consensus estimates of $1.19 by $0.23. The business had revenue of $761.70 million during the quarter, compared to analyst estimates of $729.89 million. Insulet had a return on equity of 26.87% and a net margin of 10.44%.Insulet’s revenue for the quarter was up 33.9% on a year-over-year basis. During the same quarter last year, the company posted $1.02 EPS. Insulet has set its FY 2026 guidance at 6.210- EPS. Equities analysts anticipate that Insulet Corporation will post 6.46 earnings per share for the current year.

Analysts Set New Price Targets

Several brokerages have commented on PODD. Canaccord Genuity Group dropped their price target on shares of Insulet from $435.00 to $249.00 and set a “buy” rating on the stock in a research report on Thursday, May 7th. Leerink Partners reduced their price objective on shares of Insulet from $360.00 to $247.00 in a research report on Thursday, May 7th. Robert W. Baird lowered their price objective on shares of Insulet from $360.00 to $248.00 in a research note on Thursday, May 7th. Piper Sandler dropped their target price on shares of Insulet from $360.00 to $210.00 in a report on Wednesday, May 6th. Finally, UBS Group set a $219.00 target price on shares of Insulet in a report on Thursday, June 11th. Twenty-two analysts have rated the stock with a Buy rating, four have given a Hold rating and two have given a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $237.83.

Insider Buying and Selling

In other news, Director Timothy C. Stonesifer bought 2,790 shares of the firm’s stock in a transaction on Wednesday, June 3rd. The stock was bought at an average cost of $143.51 per share, for a total transaction of $400,392.90. Following the completion of the acquisition, the director directly owned 9,041 shares in the company, valued at $1,297,473.91. This represents a 44.63% increase in their position. The purchase was disclosed in a filing with the SEC, which is available at this hyperlink. Corporate insiders own 0.36% of the company’s stock.

Key Headlines Impacting Insulet

Here are the key news stories impacting Insulet this week:

• Positive Sentiment: Insulet announced the launch of Omnipod 5 and Omnipod Discover in Spain, expanding access to its tubeless diabetes technology and supporting the company’s international growth story. Article Title
• Positive Sentiment: Deutsche Bank initiated coverage on PODD with a Buy rating and a $190 price target, signaling Wall Street sees meaningful upside from current levels. Article Title

About Insulet

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.